David Klein, Click Therapeutics CEO
Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M
Boehringer Ingelheim inked a massive collaboration with digital therapeutics company Click Therapeutics two years ago — and now its expanding.
On Monday, the German pharma announced the launch of an “expanded collaboration” between Boehringer Ingelheim and Click to develop and commercialize a second “prescription-based digital therapeutic.” The collaboration will center on schizophrenia and aim to combine multiple therapeutic interventions for use with pharmaceutical therapy to help people with the disease.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters